Lv2
200 积分 2024-10-23 加入
KRAS mutation-driven O-GlcNAcylation of CLDN18.2 enhances the progression of pancreatic cancer and reduces the efficacy of CLDN18.2-targeted therapy
18天前
已关闭
KRAS mutation-driven O-GlcNAcylation of CLDN18.2 enhances the progression of pancreatic cancer and reduces the efficacy of CLDN18.2-targeted therapy
18天前
已完结
Spatial profiling of patient-matched HER2 positive gastric cancer reveals resistance mechanisms to targeted therapy
18天前
已完结
Antibody–Drug Conjugates Synergize with Agonist Anti-CD137 Monoclonal Antibodies in Solid Tumors
27天前
已完结
Targeting Sialylation Enhances the Therapeutic Efficacy of the Nectin-4–Targeted Antibody–Drug Conjugate Enfortumab Vedotin in Bladder Cancer
28天前
已完结
Antibody–Exatecan Conjugates with a Novel Self-immolative Moiety Overcome Resistance in Colon and Lung Cancer
1个月前
已完结
Payload Diversification Overcomes Resistance and Guides Sequential Antibody–Drug Conjugate Therapy in Breast Cancer
1个月前
已完结
First-Line HER2 ADC and Anti–PD-1 Plus Chemo Shows Efficacy in Gastric Cancer
1个月前
已关闭
RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer
1个月前
已完结
First-Line HER2 ADC and Anti-PD-1 Plus Chemo Shows Efficacy in Gastric Cancer
1个月前
已关闭
皖公网安备34019202002308
